Serum erythropoietin in hepatocellular carcinoma.

被引:0
|
作者
Malaguarnera, M [1 ]
Bentivegna, P [1 ]
DiFazio, I [1 ]
Laurino, A [1 ]
Romano, M [1 ]
Trovato, BA [1 ]
机构
[1] UNIV ETUD CATANIA, DEPT MED INTERNE & GERIATR, CATANIA, ITALY
关键词
erythropoietin; hepatocellular carcinoma; anemia;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hemopoietic alterations may occur during tumoral diseases, determining anemia. In most cases, serum EPO levels were lower than normal values. Hepatocellular carcinoma (HCC), one of the most frequent malignancies world-wide, is often characterized by mild anemia and increased serum EPO levels. We studied 30 HCC patients and 20 healthy subjects. We found that HCC patients presented higher serum EPO levels than healthy controls. In HCC patients, there was a significant inverse correlation between serum EPO levels and red blood cell count or hemoglobin levels. We postulated that the elevated serum EPO levels observed in these patients may be due to reduced hepatic clearance of EPO, and to the influence of cytokine-mediated inflammatory factors.
引用
收藏
页码:977 / 980
页数:4
相关论文
共 50 条
  • [1] Hepatocellular carcinoma.
    Lemoine, A
    Azoulay, D
    Jezequel-Cuer, M
    Debuire, B
    [J]. PATHOLOGIE BIOLOGIE, 1999, 47 (09): : 903 - 910
  • [2] Hepatocellular carcinoma.
    Venook A.P.
    [J]. Current Treatment Options in Oncology, 2000, 1 (5) : 407 - 414
  • [3] SERUM ERYTHROPOIETIN CONCENTRATIONS IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA
    KEW, MC
    FISHER, JW
    [J]. CANCER, 1986, 58 (11) : 2485 - 2488
  • [4] Serum transforming growth factor-alpha in hepatocellular carcinoma.
    Law, NM
    Lim, CC
    Tan, CK
    Lai, OF
    Ng, HS
    [J]. HEPATOLOGY, 1996, 24 (04) : 1639 - 1639
  • [5] Serum γ-glutamyl transpeptidase and prognosis of patients resected for hepatocellular carcinoma.
    Uzzau, A
    Intini, S
    Toniutto, P
    Sistu, M
    Tramonte, F
    Fabris, C
    Pirisi, M
    [J]. HEPATOLOGY, 1998, 28 (04) : 766A - 766A
  • [6] Evaluation of circulating Activin-A as a serum marker of hepatocellular carcinoma.
    Pirisi, M
    Fabris, C
    Luisi, S
    Santuz, M
    Soardo, G
    Toniutto, P
    Vitulli, D
    Federico, E
    Del Forno, M
    Petraglia, F
    [J]. HEPATOLOGY, 1998, 28 (04) : 761A - 761A
  • [7] Detection of serum and intrahepatic hepatocyte growth factor in hepatocellular carcinoma.
    Komine, F
    Moriyama, M
    Hayashi, N
    Suzuki, K
    Tanaka, N
    Ohkubo, H
    Ishizuka, H
    Arakawa, Y
    Sugitani, M
    Uchida, T
    [J]. GASTROENTEROLOGY, 1996, 110 (04) : A1239 - A1239
  • [8] Evaluation of serum apoptotic markers in hepatic cirrhosis and hepatocellular carcinoma.
    Hady, AAA
    Zekry, NBA
    El Shanawani, FM
    Yehia, HA
    Ismail, A
    Hassan, MM
    [J]. CLINICAL CHEMISTRY, 2004, 50 (06) : A153 - A153
  • [9] The management of hepatocellular carcinoma.
    Cerezo, FJM
    Garreta, J
    Miralbes, M
    Balanzo, J
    Enriquez, J
    [J]. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1996, 88 (10) : 687 - 694
  • [10] Serum adiponectin and overall survival in a prospective cohort of patients with hepatocellular carcinoma.
    Siegel, Abby B.
    Goyal, Abhishek
    Hidalgo, Rosa Denisse
    Wang, Shuang
    Neugut, Alfred I.
    Brown, Robert S.
    Emond, Jean
    Kato, Tomoaki
    Samstein, Benjamin
    Dove, Lorna
    Santella, Regina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)